Phaseline

Companies › Pharming Technologies

Pharming Technologies: clinical trials, targets and expected readouts

2 active drug programs in 6 registered trials: 4 Phase 2, 2 Phase 3; Immunology, Other, Neurology, Metabolic and endocrine; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Leniolisib
PI3-kinase p110-delta subunit inhibitor
PIK3CDPhase 3APDS; Primary Immunodeficiency Disorders (PIDs); PIDs Linked to PI3KNov 2026
KL1333 (napazimone)
LONP1 activator
LONP1Phase 2Primary Mitochondrial Disease; Mitochondrial DiseasesOct 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06549114LeniolisibPhase 2Primary Immunodeficiency Disorders (PIDs)ImmunologyJun 2026
NCT05438407LeniolisibPhase 3APDSImmunologyNov 2026
NCT05650229KL1333 (napazimone)Phase 2Primary Mitochondrial DiseaseMetabolic and endocrineOct 2027
NCT05693129LeniolisibPhase 3APDSImmunologyJul 2028
NCT07514338KL1333 (napazimone)Phase 2Mitochondrial DiseasesNeurologyMar 2029
NCT06990529LeniolisibPhase 2PIDs Linked to PI3KOtherAug 2029

Targets

PIK3CD (1) LONP1 (1)

Companies with the same targets

Incyte Biosciences Japan GK Incyte Kyowa Kirin Rhizen Pharmaceuticals SecuraBio

Companies built like this

Energenesis Biomedical Laboratorios Silanes S.A. de C.V. Idorsia Pharmaceuticals PTC Therapeutics Cartesian Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.